头颈部鳞状细胞癌监测计算机断层扫描中颈部影像报告和数据系统3类的发生率、活检率及预测性能
该回顾性队列研究分析了2020年2月至2021年2月间580例颈部CT的NI-RADS报告,其中39例(7%)CT(37例患者)归为NI-RADS 3类。51个NI-RADS 3类病灶中36个(71%)为复发,活检率45%,NI-RADS 3类对复发鳞状细胞癌的阳性预测值为71%。
要点
- NI-RADS 3类病灶发生率为7%(39/580例CT)。
- NI-RADS 3类病灶活检率为45%(23/51个病灶)。
- NI-RADS 3类对复发鳞状细胞癌的阳性预测值为71%(36/51个病灶)。
核心结论
- 本队列中NI-RADS 3类病灶发生率为7%,活检率为45%,对复发鳞状细胞癌的总体阳性预测值为71%;3类病灶与显著的鳞状细胞癌复发风险相关,应据此进行管理。
研究设计与样本
- 回顾性队列研究,纳入2020年2月至2021年2月期间580例报告NI-RADS的颈部CT,其中39例(7%)CT来自37例患者(28男,9女,平均年龄66.6岁)构成研究队列。
主要发现
- 39例(7%)CT(37例患者)归为NI-RADS 3类,共51个NI-RADS 3类病灶(32个原发灶,19个颈部)。
- 23个病灶(45%)接受了活检,其中17个(74%)为复发性鳞状细胞癌阳性;1例活检无法诊断,临床判定为复发。
- 28个(55%)未活检病灶中,18个(64%)最终按临床判定复发进行治疗。
- 51个NI-RADS 3类病灶中,36个(71%)为复发。
关键数值与推荐
- NI-RADS 3类推荐「若有临床指征,则行活检」。
- NI-RADS 3类病灶发生率为7%(39/580例CT)。
- NI-RADS 3类病灶活检率为45%(23/51个病灶)。
- NI-RADS 3类对复发鳞状细胞癌的阳性预测值为71%(36/51个病灶)。
临床怎么用
- 原文结论指出NI-RADS 3类病灶与显著的鳞状细胞癌复发风险相关,应据此进行管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Neck Imaging Reporting and Data System (NI-RADS) is a radiology reporting system for head and neck cancer surveillance. Imaging findings of high suspicion for recurrence are assigned Category 3 and recommended for "Biopsy, if clinically indicated." After implementing NI-RADS for surveillance neck computed tomography (CT), our objectives are to determine the incidence of squamous cell carcinoma (SCC) Category 3 lesions in the year post-implementation, the associated biopsy rate, and the positive predictive value of NI-RADS 3 for SCC recurrence. STUDY DESIGN: Retrospective cohort study. METHODS: Neck CTs reported with NI-RADS between February 2020 and February 2021 were reviewed to identify patients undergoing surveillance for SCC assigned NI-RADS 3. Cancer recurrence, defined as positive biopsy result or treatment of clinically determined recurrence, was determined by electronic medical record review. RESULTS: During the study period, 580 neck CTs were reported with NI-RADS, of which 39 (7%) CTs obtained in 37 unique patients (28 male, 9 female, mean age 66.6 years) formed the study cohort. Biopsies were obtained in 23 lesions (45%), of which 17 (74%) were positive for recurrent SCC. One nondiagnostic biopsy was clinically determined to represent recurrence. Of 28 (55%) lesions not biopsied, 18 (64%) were ultimately treated as clinically determined recurrence. Thus, among 51 individual NI-RADS 3 lesions (32 primary, 19 neck), 36 (71%) represented recurrence. CONCLUSION: The incidence of NI-RADS 3 lesions in our cohort was 7%. The biopsy rate was 45%, and the overall positive predictive value of NI-RADS 3 for recurrent SCC was 71%. Category 3 lesions are associated with substantial SCC recurrence risk and should be managed accordingly. LEVEL OF EVIDENCE: 4 Laryngoscope, 132:1792-1797, 2022.
引用
- Johansson ED, Hughes RT, Meegalla NT, et al. Neck Imaging Reporting and Data System Category 3 on Surveillance Computed Tomography: Incidence, Biopsy Rate, and Predictive Performance in Head and Neck Squamous Cell Carcinoma. Laryngoscope. 2022. PMID: 35043989. doi:10.1002/lary.30025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。